# Phosphorylation: Kinases and Phosphatases

> A stable, removable phosphate changes protein behavior through its charge and shape. This lesson builds that physical idea, shows how kinase and phosphatase rates together set the phosphorylated fraction, and uses it to explain activity, docking, location and priming. You will finish able to plan experiments that show a protein is phosphorylated, map the modified residue and test what the phosphate does.

Course: Cell Signaling (The parts: switches and wiring). Level: advanced university and graduate. About 15 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/phosphorylation-switch/
Note: parts of this lesson are still being checked ("Under review").

Builds on: Circuits: Amplification, Feedback, Adaptation and Switches · Binding: Affinity, Occupancy and Dose–Response

## What you'll learn

- Explain why a phosphate group makes a good switch: two negative charges, a stable bond, separate enzymes to add and remove it, and a plentiful donor in ATP.
- Name the residues that carry phosphate in animal proteins and the four things a phosphate can do: change activity through shape, create a docking site, change location, and prime another modification.
- Explain why a cell needs both kinases and phosphatases, and what the numbers of each suggest about how they are controlled.
- Describe how you would show that a protein is regulated by phosphorylation at a particular site.

The first film shows the switch; this page adds the chemistry, numbers and evidence.

> **The one idea.** A stable, removable phosphate changes protein behavior through its charge and shape.
>
> *Scope:* regulatory phosphorylation of proteins, especially the well-studied serine, threonine and tyrosine sites in animal signaling. The charge is the main handle, but partners also read the phosphate’s shape and the residues around it, which is why aspartate is only a rough mimic. It may favor activity or inhibition; it is not an automatic on signal.

## Write the mark, erase the mark

A cell can change what a protein does by making more of it, which is slow, by binding a small molecule to it, or by attaching a chemical group after the protein is made. That last route is a **covalent modification**, and signaling pathways use phosphate most. The first film’s two reactions:

> **protein-OH + ATP → protein-O-PO3(2−) + ADP (kinase)**
>
> **protein-O-PO3(2−) + H2O → protein-OH + Pi (phosphatase)**

A **protein kinase** moves the end, or gamma, phosphate of ATP onto the protein; a **protein phosphatase** removes it with water. ATP sits at millimolar concentration in the cell. Near pH 7 the attached phosphate carries close to two negative charges where there were none.

Most protein-bound phosphate sits on serine and threonine. Tyrosine carries well under 1% of it in a cell, about 2% of mapped sites, which kept phosphotyrosine hidden until 1979. Mammals also phosphorylate histidine, but the acid in standard methods strips that phosphate, so how common phosphohistidine is remains unclear.

## Four consequences of one added phosphate

The phosphate has no activity of its own; the protein and its neighbours respond to it. The first film’s four outcomes, case by case:

**Activity through shape.** In muscle glycogen phosphorylase the phosphate lands on serine 14, near the chain’s start and far from the catalytic site, yet it favors the active form. The same mark inhibits glycogen synthase.

**A docking site.** A partner whose pocket recognises the phosphorylated side chain can dock; a later lesson covers those pockets.

*Figure (AI-generated illustration).* A phosphate can create a docking surface that brings two proteins together without changing either protein's catalytic rate. Image: a two-step schematic. Before phosphorylation, a protein and a partner with a recognition pocket are separate. After phosphate is added to a side chain, the phosphorylated side chain docks in the partner's pocket, bringing the two proteins together.

**A new location.** Nuclear factor of activated T cells (NFAT) is a transcription factor, a protein that switches genes on. It waits in the cytoplasm with many phosphates hiding its nuclear-entry sequence. When calcineurin removes them, NFAT enters the nucleus: the eraser carries the signal.

**Predict.** If calcineurin is inhibited while the kinases keep working, where should NFAT accumulate?

> **Check your prediction.** In the cytoplasm. Its phosphates remain, so the sequence that sends NFAT into the nucleus stays hidden.

*Figure (AI-generated illustration).* Calcineurin removes NFAT's phosphates, exposing its nuclear-entry sequence, so the erasing enzyme carries this signal. Image: three schematic stages show phosphorylated NFAT in the cytoplasm with its nuclear entry sequence hidden, calcineurin removing attached phosphates so the sequence becomes exposed, and NFAT entering the nucleus.

**Priming another modification.** Glycogen synthase kinase 3, for example, prefers a serine or threonine four residues before a site another kinase has phosphorylated. If the priming kinase answers a different signal, the substrate can wait for two inputs.

These outcomes concern single copies; the second film asks what sets the fraction of a population carrying the mark.

**Film transcript: Two Enzymes Set the Level**

### Film transcript: Two Enzymes Set the Level

Each outcome so far concerned one protein copy. But a cell controls a whole population. If a kinase writes the mark, why cannot kinase activity alone predict the level? Follow a fixed population while writing and erasing happen together.

Divide the population into an unphosphorylated pool and a phosphorylated pool. The kinase moves available copies toward the phosphorylated side. The phosphatase moves marked copies back. The total number of protein copies stays fixed while membership keeps changing. Use the simplest model: one site, a fixed pool, and effective first-order rates. Kinase flow depends on how many unmarked copies remain.

Phosphatase flow depends on how many marked copies exist. A steady level appears when those opposing flows match, although individual copies still cycle. Make a prediction. Keep kinase activity fixed but slow the phosphatase. Which way will the phosphorylated fraction move?

The fraction rises. Writing now outruns erasing at the old level, so marked copies accumulate. As that pool grows, phosphatase flow also grows. A new steady level appears when the flows match again. Inhibiting an eraser can therefore mimic activating a writer. The balance has a compact rule. At steady state, the kinase rate divided by the sum of both rates gives the phosphorylated fraction. Compute that rule across possible kinase rates. The curve rises smoothly and approaches a ceiling rather than jumping at a fixed threshold. The same enzymes also set response speed. Increase both rates by the same factor. The steady fraction stays put because their ratio is unchanged.

The population reaches that level faster because the opposing flows are larger. Faster cycling spends ATP faster. A signal can act at either side of the cycle. It may activate the kinase, inhibit the phosphatase, or later activate the phosphatase to end the response. Measuring only the writer misses those possibilities.

Measure the substrate's modification and both opposing activities. Keep the model's boundary visible. It assumes a fixed pool, a single site, and effective first-order rates. Saturated enzymes, several sites, feedback, or protein turnover can change the response. Start with the simple balance, then test whether the system obeys it. When phosphorylation rises, ask what changed on both sides. More kinase activity is only a possible answer. Less phosphatase activity can produce the same direction of change. The observed level belongs to the cycle, not to either enzyme alone. That is why the substrate measurement matters.

From the film

- Phosphorylation level depends on both the kinase and the phosphatase.
- At simple first-order rates, their ratio sets the steady phosphorylated fraction.
- Either activating the kinase or inhibiting the phosphatase can raise that fraction.
- Faster opposing rates make the level settle faster but spend more ATP.

## How much protein carries the phosphate?

**Predict.** A kinase works at 0.6 per minute against a phosphatase at 0.2 per minute. A drug cuts only the kinase rate tenfold, to 0.06 per minute. Does the phosphorylated fraction fall tenfold?

The **phosphorylated fraction**, *f*, is the share of a protein pool carrying phosphate at the measured site. Take the second film’s simplest model: one site, a fixed total pool and effective first-order rates, with no saturated enzymes and no multisite network. Fraction *(1 − f)* is available to the kinase:

> **rate in = k(kinase) × (1 − f)**
>
> **rate out = k(phosphatase) × f**

At steady state the rates match, so:

> **f = k(kinase) / (k(kinase) + k(phosphatase))**

> **Check your prediction.** No. Before the drug, f = 0.6 / (0.6 + 0.2) = 0.75. After it, f = 0.06 / (0.06 + 0.2), about 0.23. A tenfold cut in kinase rate gives only about a threefold fall, because the phosphatase rate stays in the denominator.

So the phosphorylation level depends on both the kinase and the phosphatase, not on kinase activity alone. Because the summed rates set how fast the level settles, a pathway that must shut off in seconds needs a fast phosphatase; running it constantly costs ATP, so some pathways switch it on only when the signal ends.

## How the enzymes find the right targets

The human genome holds about 518 protein-kinase genes. Most encode serine/threonine kinases; about 90 encode tyrosine kinases. The tyrosine-phosphatase family is about as large by count, but only about 38 members are classical enzymes that read only phosphotyrosine, and many erasers are built like membrane receptors.

Serine/threonine counts are lopsided: hundreds of kinases but only a few dozen genes for phosphatase catalytic subunits. Specificity comes from partners. PP1, a major catalytic subunit, is encoded by three genes yet pairs with well over a hundred regulatory subunits, which choose its location and substrates. The counts suggest that tyrosine dephosphorylation is steered more by enzyme choice, and serine/threonine dephosphorylation by company. That is an inference from counts, not proof.

## Build the evidence: detect, map, test

Three claims need different evidence: the protein carries phosphate, a particular residue carries it, and changing that site changes function.

**Predict.** A stimulated sample shows an extra, slower band on an SDS gel. What control would tie that band to phosphate, and what would it still leave open?

> **Check your prediction.** Treat half the sample with purified phosphatase. If the slow band collapses into the fast one and a phosphatase inhibitor prevents that, the shift depends on phosphate. The residue and the function remain open.

**Detect it.** A phosphorylated protein often runs more slowly on an SDS gel, which sorts proteins by apparent size; the phosphatase test above is the quick first check. Confirm that the protein carries phosphate by growing cells with radioactive phosphate (32P), pulling the protein out with an antibody and checking for label. A site found only in a test tube must still be confirmed in cells.

**Map it.** Break the labelled protein into amino acids and separate them to learn which kind of residue carries the label. Change candidate serine or threonine residues to alanine, or tyrosine to phenylalanine, removing the hydroxyl, and ask which change removes the label or shift. [Mass spectrometry](https://stemhop.com/methods/mass-spectrometry/) is faster: each phosphate adds 80 Da to a peptide, and peptide fragments usually locate the residue.

**Predict.** A peptide from the upper gel band is 240 Da heavier than the matching peptide below, and the band runs an apparent 3 kDa higher. How many phosphates does the peptide carry?

> **Check your prediction.** Three, because 240 / 80 = 3. Three phosphates add only 0.24 kDa; the 3 kDa is apparent migration, not mass, so it cannot be converted into a phosphate count.

**Test function.** Compare an alanine mutant, which cannot be phosphorylated, with an aspartate mutant, whose negative charge roughly imitates a persistent phosphate. Ask which of the four consequences the mimic reproduces: activity, docking, location or priming.

**Predict.** A kinase activates enzyme E. The serine-to-alanine mutant no longer responds to the kinase, but the serine-to-aspartate mutant is no more active than the unstimulated normal enzyme. What can you conclude?

> **Check your prediction.** The alanine result points to this serine as the site that matters. The silent mimic proves little: aspartate carries one charge where phosphate carries two, it is smaller, and a partner may not recognise it. Seek another line of evidence.

The normal protein should respond to kinase inhibition or activation; the alanine mutant should not. Inhibitors can narrow the writer list. Kevan Shokat’s [analog-sensitive kinases](https://stemhop.com/methods/analog-sensitive-kinase/) are engineered to accept an ATP analog that normal kinases cannot use, so they label only direct targets.

Work this approach on a real case: the transcription factor in Deppmann and colleagues’ 2003 paper, which combined a phosphatase-sensitive [gel shift](https://stemhop.com/methods/immunoprecipitation-and-binding-assays/), serine and threonine sites and a serine-to-aspartate mimic.

## When the switch breaks: kinases in disease and the clinic

A lecture slide claims nearly every kinase has been linked to disease, a slight stretch: many have, but much of the kinome is poorly studied. A common cancer pattern is a gain-of-function mutation that leaves a kinase, often a receptor tyrosine kinase, active without a signal and telling the cell to grow. Losing a phosphatase can cause similar damage because the brake is gone.

A second slide calls kinases “highly conserved: target for lots of drugs.” The ATP cleft between the two lobes is snug and mostly greasy, so small drugs can fill it. Imatinib, approved in 2001 for chronic myeloid leukemia, binds BCR-ABL, the overactive fusion kinase made when a chromosome rearrangement joins two genes. Gefitinib and erlotinib, approved in the United States in 2003 and 2004, target the epidermal growth factor (EGF) receptor similarly.

Conservation makes selectivity hard: a molecule fitting one ATP pocket may fit some of the other 517, causing side effects, and it must compete with millimolar cellular ATP. Chemists find selectivity at the edges of the pocket, where kinases differ, or in inactive shapes that only some kinases adopt. Imatinib binds Abl in an inactive conformation, helping explain why it spares most other kinases.

## Going deeper

### How reversible protein phosphorylation emerged

**1943.** Carl and Gerty Cori and Arda Green in St. Louis crystallized glycogen phosphorylase, the muscle enzyme that releases glucose units from glycogen. Phosphorylase *a* was active alone; *b* required AMP. An enzyme turned *a* into *b*. They thought it removed bound AMP; it was a phosphatase.

**1954.** Burnett and Kennedy described a liver enzyme moving phosphate from ATP onto casein, the first protein kinase described.

**1955.** Edmond Fischer and Edwin Krebs in Seattle set out to make phosphorylase *a* by the Coris’ recipe. They kept getting *b* unless they filtered the extract through paper. The paper leached calcium, and standing extracts ran out of ATP. Over the next few years, conversion of *b* to *a* proved to be an enzyme moving one phosphate from ATP onto one serine on each chain. The overview lesson on signal transduction tells the full story.

**1979 to 1980.** Tony Hunter saw a radioactive spot between phosphoserine and phosphothreonine markers; his phosphotyrosine standard matched it. He and Bartholomew Sefton showed that Src, the cancer-causing protein of Rous sarcoma virus, phosphorylates tyrosine. Within the year, H. Ushiro and Stanley Cohen used tumour-cell membranes without living cells to show that epidermal growth factor (EGF) switches on the same activity. It was later traced to the cell’s own EGF receptor.

**1988.** Nicholas Tonks, working with Fischer, purified PTP1B, the first protein tyrosine phosphatase, from human placenta. Its sequence resembled part of CD45, a white-blood-cell surface protein, showing that a phosphatase could be receptor-like.

### Pseudokinases and family counts

About one in ten human kinases, called pseudokinases, has lost catalytic activity and instead works by binding other proteins.

Of the roughly 90 human tyrosine kinases, 58 are receptors spanning the plasma membrane with the kinase inside. The tally “107 PTPs to counteract 90 protein tyrosine kinases (PTKs)” (protein tyrosine phosphatases and kinases) counts the whole phosphatase family: only about 38 are classical phosphotyrosine-specific enzymes, and relatives such as phosphatase and tensin homolog (PTEN) prefer substrates other than proteins.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/phosphorylation-switch/
